AstraZeneca announces positive results from brodalumab study

12th May 2014 07:12

AstraZeneca said the Phase III Amagine-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints.Results showed that 83.3% of patients in the 210 mg group and 60.3 patients in the 140 mg group achieved at least a 75% improvement from baseline in disease severity at week 12 and achieved clear or almost clear skin."Data from the Amagine-1 study suggest that brodalumab may offer a new level of efficacy for patients with moderate-to-severe plaque psoriasis, a disease that affects more than 100 million people globally," said Sean Harper, Executive Vice President of Research and Development at Amgen. "This is the first read-out from our Phase III psoriasis clinical programme and we look forward to obtaining additional Phase III data from our two head-to-head studies versus ustekinumab later this year."RD